Indication
Myocardial infarction prevention
Myocardial infarction prevention refers to clinical strategies aimed at averting acute myocardial necrosis caused by prolonged, severe ischemia within the cardiovascular system. Read more about Myocardial infarction prevention
484 drugs 188 manufacturers
Drugs that treat it
Common Myocardial infarction prevention therapies.
ASPIRIN, BUFFERED (aspirin/calcium carbonate/magnesium)
ASPIRIN, BUFFERED (aspirin/calcium carbonate/magnesium)
ASPIRIN, BUFFERED (aspirin/magnesium carbonate/dihydroxyaluminum aminoacetate)
ATORVASTATIN CALCIUM
TRI-BUFFERED ASPIRIN (aspirin/calcium carbonate/magnesium)
CHILDREN'S ASPIRIN (aspirin)
CHILDREN'S ASPIRIN (aspirin)
CHILDREN'S ASPIRIN (aspirin)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMyocardial infarction prevention refers to clinical strategies aimed at averting acute myocardial necrosis caused by prolonged, severe ischemia within the cardiovascular system.
This indication encompasses primary prevention in individuals with elevated cardiovascular risk factors—such as diabetes, dyslipidemia, or hypertension—and secondary prevention in patients with established coronary artery disease, prior acute coronary syndromes, or revascularization.
Pathophysiologically, it focuses on stabilizing vulnerable coronary atherosclerotic plaques, mitigating endothelial inflammation, suppressing platelet aggregation, and maintaining an adequate balance between myocardial oxygen supply and demand to deter acute thrombotic occlusion.
- nih.gov
Myocardial infarction prevention refers to clinical strategies aimed at averting acute myocardial necrosis caused by prolonged, severe ischemia within the cardiovascular system
- nih.gov
Myocardial infarction prevention refers to clinical strategies aimed at averting acute myocardial necrosis caused by prolonged, severe ischemia within the cardiovascular system Pathophysiologically, it focuses on stabilizing vulnerable coronary atherosclerotic plaques, mitigating endothelial inflammation, suppressing platelet aggregation, and maintaining an adequate balance between myocardial oxygen supply and demand to deter acute thrombotic occlusion
- nih.gov
This indication encompasses primary prevention in individuals with elevated cardiovascular risk factors—such as diabetes, dyslipidemia, or hypertension—and secondary prevention in patients with established coronary artery disease, prior acute coronary syndromes, or revascularization Pathophysiologically, it focuses on stabilizing vulnerable coronary atherosclerotic plaques, mitigating endothelial inflammation, suppressing platelet aggregation, and maintaining an adequate balance between myocardi...
- nih.gov
This indication encompasses primary prevention in individuals with elevated cardiovascular risk factors—such as diabetes, dyslipidemia, or hypertension—and secondary prevention in patients with established coronary artery disease, prior acute coronary syndromes, or revascularization
Personalize your experience
Follow Myocardial infarction prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.